Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

13G Filing: Biotechnology Value Fund LP and CytomX Therapeutics Inc (CTMX)

You can access the original SEC filing by clicking here.

Ownership Summary Table

Name Sole Voting Power Shared Voting Power Sole Dispositive Power Shared Dispositive Power Aggregate Amount Owned Power Percent of Class
Biotechnology Value Fund 0 0 941,783 941,783 2.6%
Biotechnology Value Fund II 0 0 608,749 608,749 1.7%
Biotechnology Value Trading Fund OS 0 0 171,334 171,334 Less%
BVF Partners OS Ltd 0 0 171,334 171,334 Less%
BVF Partners 0 0 2,026,998 2,026,998 5.5%
BVF Inc 0 0 2,026,998 2,026,998 5.5%
Mark N. Lampert 0 0 2,026,998 2,026,998 5.5%

Page 1 of 13 – SEC Filing



Washington, D.C. 20549


(Rule 13d-102)


TO RULES 13d-1(b), (c),


(Amendment No.

CytomX Therapeutics, Inc.

 (Name of Issuer)

Common Stock, $0.00001 par value

 (Title of Class of Securities)

23284F 10 5

 (CUSIP Number)

June 19, 2017

 (Date of Event Which Requires Filing of this

Check the appropriate box
to designate the rule pursuant to which this Schedule is filed:

   Rule 13d-1(b)
   Rule 13d-1(c)
   Rule 13d-1(d)

The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to
the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided
in a prior cover page.

The information required
on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities
Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject
to all other provisions of the Act (however, see the Notes).

Follow Cytomx Therapeutics Inc.
Trade (CTMX) Now!

DOWNLOAD FREE REPORT: Warren Buffett's Best Stock Picks

Let Warren Buffett, George Soros, Steve Cohen, and Daniel Loeb WORK FOR YOU.

If you want to beat the low cost index funds by 19 percentage points per year, look no further than our monthly newsletter.In this free report you can find an in-depth analysis of the performance of Warren Buffett's entire historical stock picks. We uncovered Warren Buffett's Best Stock Picks and a way to for Buffett to improve his returns by more than 4 percentage points per year.

Bonus Biotech Stock Pick: You can also find a detailed bonus biotech stock pick that we expect to return more than 50% within 12 months.
Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.